NCT07093008View on ClinicalTrials.gov

Comparing the Extent to Which AQ280 is Made Available in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 13, 2025

Primary Completion Date

July 16, 2025

Study Completion Date

July 22, 2025

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

AQ280 Capsule

AQ280 administered orally in capsule formulation.

DRUG

AQ280 Tablet for Oral Suspension

AQ280 administered orally in tablet for oral suspension formulation.

DRUG

Placebo Capsule

Placebo administered orally in capsule formulation.

DRUG

Placebo Tablet for Oral Suspension

Placebo administered orally in tablet for oral suspension formulation.

Trial Locations (1)

53704

Clinical Research Site, Madison

All Listed Sponsors
lead

AQILION AB

INDUSTRY